Esperion Therapeutics, Inc. (NASDAQ:ESPR) is reporting second quarter earnings results on Monday 10th August 2020, after market close.
The consensus estimates from Thomson Reuters are income of $ 1.71 per share from $ 147.97 million in revenue.
For the full year, analysts predict revenues of $ 244.75 million, while looking forward to loss of $ 5.1 per share.
Previous Quarter Performance
Esperion Therapeutics, Inc. revealed loss for the first quarter of $ 2.84 per share, from the revenue of $ 1.84 million. The quarterly revenues down 97.21 percent compared with the same quarter last year. According to street consensus, ESPR was expected to report 1Q20 loss of $ 3.29 per share from revenue of $ 0.52 million. The bottom line results beat street analysts by $ 0.45 or 13.68 percent, at the same time, top line results outshined analysts by $ 1.32 million or 253.85 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Esperion Therapeutics, Inc.
Stock Performance
According to the previous trading day, closing price of ESPR was $ 38.00, representing a 53.10 % increase from the 52 week low of $ 24.82 and a 50.64 % decrease over the 52 week high of $ 76.98.
The company has a market capital of $ 1.05 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”ESPR” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Esperion Therapeutics, Inc. will be hosting a conference call at 4:30 PM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.esperion.com
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination tablet, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH.
